Lucie Casault1, Josée Savard2, Hans Ivers3, Marie-Hélène Savard4. 1. School of Psychology, Université Laval, Québec, Québec, G1V 0A6, Canada; Centre de recherche du CHU de Québec and Centre de recherche sur le cancer, Université Laval, 11 Côte du Palais, Québec, G1R 2J6, Canada; Centre hospitalier universitaire (CHU) de Québec, 11, Côte du Palais, Québec, Québec, G1R 2J6, Canada. 2. School of Psychology, Université Laval, Québec, Québec, G1V 0A6, Canada; Centre de recherche du CHU de Québec and Centre de recherche sur le cancer, Université Laval, 11 Côte du Palais, Québec, G1R 2J6, Canada. Electronic address: josee.savard@psy.ulaval.ca. 3. School of Psychology, Université Laval, Québec, Québec, G1V 0A6, Canada; Centre de recherche du CHU de Québec and Centre de recherche sur le cancer, Université Laval, 11 Côte du Palais, Québec, G1R 2J6, Canada. 4. Centre de recherche du CHU de Québec and Centre de recherche sur le cancer, Université Laval, 11 Côte du Palais, Québec, G1R 2J6, Canada.
Abstract
OBJECTIVE: This study aimed to provide preliminary evidence on the efficacy of an early minimal cognitive-behavioural therapy for acute insomnia (mCBT-I) comorbid with cancer. METHOD: Thirty-eight patients (92% female; Mage 57; all Caucasian) with various types of cancer and having insomnia symptoms for less than 6 months were randomized to a self-administered mCBT-I condition (n=20; 6 short booklets + 3 phone consultations with a psychologist, over 6 weeks) or a no-treatment condition (n=18). Measures were completed at pre-treatment and post-treatment, as well as at 3- and 6-month follow-ups. RESULTS: All sleep parameters and the average dosage of hypnotics were significantly improved from pre- to post-treatment among treated participants, but not in control participants. mCBT-I was also associated with a significantly greater reduction of anxiety and depression symptoms, maladaptive sleep habits, and erroneous beliefs about sleep, as well as with a significantly greater improvement of subjective cognitive functioning. A greater proportion of mCBT-I participants than controls met the criteria for a clinical remission at post-treatment. Therapeutic gains of mCBT-I were well sustained up to 6 months after the intervention. CONCLUSIONS: This study supports the efficacy of an early minimal CBT-I to treat acute insomnia comorbid with cancer.
RCT Entities:
OBJECTIVE: This study aimed to provide preliminary evidence on the efficacy of an early minimal cognitive-behavioural therapy for acute insomnia (mCBT-I) comorbid with cancer. METHOD: Thirty-eight patients (92% female; Mage 57; all Caucasian) with various types of cancer and having insomnia symptoms for less than 6 months were randomized to a self-administered mCBT-I condition (n=20; 6 short booklets + 3 phone consultations with a psychologist, over 6 weeks) or a no-treatment condition (n=18). Measures were completed at pre-treatment and post-treatment, as well as at 3- and 6-month follow-ups. RESULTS: All sleep parameters and the average dosage of hypnotics were significantly improved from pre- to post-treatment among treated participants, but not in control participants. mCBT-I was also associated with a significantly greater reduction of anxiety and depression symptoms, maladaptive sleep habits, and erroneous beliefs about sleep, as well as with a significantly greater improvement of subjective cognitive functioning. A greater proportion of mCBT-Iparticipants than controls met the criteria for a clinical remission at post-treatment. Therapeutic gains of mCBT-I were well sustained up to 6 months after the intervention. CONCLUSIONS: This study supports the efficacy of an early minimal CBT-I to treat acute insomnia comorbid with cancer.
Authors: Kevin T Liou; James C Root; Sheila N Garland; Jamie Green; Yuelin Li; Q Susan Li; Philip W Kantoff; Tim A Ahles; Jun J Mao Journal: Cancer Date: 2020-04-22 Impact factor: 6.860
Authors: Christina S McCrae; Ashley F Curtis; Jacob M Williams; Natalie D Dautovich; Joseph P H McNamara; Ashley Stripling; Joseph M Dzierzewski; Richard B Berry; Karin M McCoy; Michael Marsiske Journal: Behav Sleep Med Date: 2019-06-15 Impact factor: 2.964
Authors: Manu Thakral; Michael Von Korff; Susan M McCurry; Charles M Morin; Michael V Vitiello Journal: Sleep Med Rev Date: 2019-11-09 Impact factor: 11.609
Authors: Debra L Barton; Pamela J Atherton; Daniel V Satele; Rui Qin; Shaker Dakhil; Teri Pipe; Timothy Hobday; Kelli Fee-Schroeder; Charles L Loprinzi Journal: Support Care Cancer Date: 2020-04-19 Impact factor: 3.603
Authors: Terri S Armstrong; Marcia Y Shade; Ghislain Breton; Mark R Gilbert; Anita Mahajan; Michael E Scheurer; Elizabeth Vera; Ann M Berger Journal: Neuro Oncol Date: 2017-03-01 Impact factor: 12.300
Authors: Oxana Palesh; Caroline Scheiber; Shelli Kesler; Michelle C Janelsins; Joseph J Guido; Charles Heckler; Mallory G Cases; Jessica Miller; Nick G Chrysson; Karen M Mustian Journal: Br J Cancer Date: 2018-07-20 Impact factor: 7.640
Authors: Helena R Bean; Lesley Stafford; Ruth Little; Justine Diggens; Maria Ftanou; Marliese Alexander; Prudence A Francis; Bei Bei; Joshua F Wiley Journal: Trials Date: 2020-03-27 Impact factor: 2.279